Clinical research of CVAD regimens sequential therapy on multiple myeloma

Abstract

Objective To investigate the efficacy and safety of cyclophosphamide + pirarubicin + vindesine + dexamethasone (CVAD) regimen on multiple myeloma (MM). Methods Thirty patients with MM from January 2011 to January 2014 of the Beijing Military Region General Hospital were selected and randomly divided into the CVAD group (treatment group) and VAD (pirarubicin + vindesine + dexamethasone) group (control group) with 15 cases in each, including 18 males and 12 females, aged from 38 to 64 years old, and the mean age was 50.5 years old. Sequential therapy was performed over eight cycles of chemotherapy and clinical efficacy between the two groups was compared. Results The total effective rates of the treatment group and control group were 80.0 % and 66.7 %, respectively. In treatment group, one patient died of complications, three cases progressed to refractory MM, and in control group, one patient died of complications, and eight cases progressed to refractory MM. The median follow-up were 22.5 months and 22.7 months, and overall survival (OS) rates were 86.7 % and 73.3 % in the treatment group and control group, respectively. Conclusion CVAD regimen could improve the clinical effect on MM and it is more effective than the VAD regimen. It is safe and worthy of clinical application. Key words: Cyclophosphamide; CVAD regimen; VAD regimen; Multiple myeloma; Sequential therapy